Claims

1. Use of dextromethorphan in the manufacture of a medicament for treating agitation in Alzheimer's disease, wherein the medicament is to be co-administered with bupropion, and wherein the human being is an extensive metabolizer of dextromethorphan.

2. The use of claim 1, wherein the bupropion is to be co-administered with dextromethorphan for at least eight consecutive days.

3. The use of claim 2, wherein, on the eighth day, the human being has an AUC of dextromethorphan 12 hours after co-administration of the bupropion with the dextromethorphan that is at least 30 times the AUC that would be achieved by administration of the same amount of the dextromethorphan without co-administration of the bupropion.

4. The use of any one of claims 1 to 3, wherein about 40 mg to about 140 mg of the dextromethorphan is to be administered per day.

5. The use of claim 4, wherein about 60 mg to about 100 mg of the dextromethorphan is to be administered per day.

6. The use of any one of claims 1 to 5, wherein about 100 mg to about 250 mg of the bupropion is to be administered per day.

7. The use of any one of claims 1 to 5, wherein about 200 mg to about 250 mg of the bupropion is to be administered per day.

8. The use of any one of claims 1 to 7, wherein bupropion is to be administered in an amount that results in a C_{max} of dextromethorphan in the human being on the eighth day that is at least 20 times the C_{max} of dextromethorphan that would be achieved by administering the same amount of the dextromethorphan without the bupropion.

9. The use of any one of claims 1 to 8, wherein the bupropion is to be co-administered with dextromethorphan once daily or twice daily.

10. The use of any one of claims 1 to 9, wherein the bupropion is to be co-administered with dextromethorphan in a single dosage form.

11. Use of dextromethorphan in the manufacture of a medicament for treating depression, wherein the medicament is to be co-administered with bupropion, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the bupropion is to be co-administered with the dextromethorphan for at least eight consecutive days, and wherein, on the eighth day, the human being has an AUC of dextromethorphan after co-administration of the bupropion with the dextromethorphan that is at least 30 times the AUC of dextromethorphan that would be achieved by administration of the same amount of dextromethorphan without co-administration of bupropion.

12. The use of claim 11, wherein, on the eighth day, the human being has a C_{max} of dextromethorphan after co-administration of the bupropion with the dextromethorphan that is at least 20 times the C_{max} of dextromethorphan that would be achieved by administration of the same amount of dextromethorphan without co-administration of the bupropion.

13. The use of claim 11 or 12, wherein about 40 mg to about 140 mg of the dextromethorphan is to be administered per day.

14. The use of claim 13, wherein about 60 mg to about 100 mg of the dextromethorphan is to be administered per day.

15. The use of any one of claims 11 to 14, wherein about 100 mg to about 250 mg of the bupropion is to be administered per day.

16. The use of any one of claims 11 to 14, wherein about 200 mg to about 250 mg of the bupropion is to be administered per day.

17. The use of any one of claims 11 to 16, wherein the bupropion is to be co-administered with the dextromethorphan in a single dosage form.